drugset / Trial / NCT03971071

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

NCT03971071

Phase 4 Completed 620 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).

Timeline

Start
2019-10-07
Primary completion
2022-12-01
Completion
2023-06-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Erenumab Monoclonal antibody 70 mg Subcutaneous
Comparator Erenumab Monoclonal antibody 140 mg Subcutaneous

Indications